PDFs by language
Our 24/7 cancer helpline provides support for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
At our National Cancer Information Center trained Cancer Information Specialists can answer questions 24 hours a day, every day of the year to empower you with accurate, up-to-date information to help you make educated health decisions. We connect patients, caregivers, and family members with valuable services and resources.
Or ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Important research on adrenal cancer currently is being done in hospitals and institutions around the world. Scientists are learning more about what causes the disease and how best to treat it. Progress in this research, however, tends to be slow because adrenal cancer is so rare. Studies of more general aspects of cancer that can be applied to adrenal cancers as well as other types of cancers are also being done.
Although adrenal cancer can be hard to study, experts are looking for new drugs that may help, as well as looking at the value of accepted treatments.
One important ongoing study (called ADIUVO) is testing the value of mitotane in treating patients with early-stage adrenal cancers that have been removed with surgery. The goal of the study is to see if mitotane lowers the chance of the cancer coming back and helps patients live longer.
Researchers are working to understand the genetic changes that cause adrenal cancers so that newer treatments can be found to target these changes.
Targeted therapy is a newer type of cancer treatment that uses drugs or other substances to attack the programming that makes cancer cells different from normal, healthy cells. Each type of targeted therapy works differently, but all alter the way a cancer cell grows, divides, repairs itself, or interacts with other cells.
A few targeted drugs have been studied for treating adrenal cancer, but so far they have not been found to be helpful. However, scientists continue to look for drugs to block the effects of certain hormones that might help adrenal cancer cells grow. One of these hormones is called insulin-like growth factor 2 (IGF2).
Some studies are being done to better understand IGF2 and other hormones to know if targeted drugs may be helpful in adrenal cancer.
Scientists are learning how changes in certain genes cause normal adrenal cortex cells to become cancerous. Understanding these genetic changes will help doctors develop better methods to diagnose this disease as well as treatments that are more effective and have fewer side effects than those currently available. Medical centers involved in research might ask their patients for blood samples and about diseases in other family members to learn more about adrenal cancer, as part of studies. These studies are different from treatment studies. The goal of these studies is to enhance research of this rare cancer, to learn more about how adrenal cancer forms, and in the future find new targets for adrenal cancer therapy.
For example, there have been several studies looking at which hereditary syndromes, such as Lynch syndrome, lead to a higher risk for adrenal cancer. (These syndromes are discussed in Risk Factors for Adrenal Cancer.) International groups are working to understand how adrenal cancer develops. Hopefully, these efforts will provide better targets for therapy.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Analysis of rare endocrine cancer reveals novel genetic alterations [press release]. National Cancer Institute (NCI) Press Office; May 9, 2016. Accessed at: https://www.cancer.gov/news-events/press-releases/2016/TCGA-adrenocortical on December 13, 2017.
Angelousi A, Dimitriadis GK, Zografos G, Nolting S, Kaltsas G, Grossman A. Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. Endocrine-related Cancer. 2017;24(6):R239-R259.
Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: A position of an international panel. J Clin Oncol. 2010;28(23):e401-402; author reply e403. Epub 2010 Jun 21.
Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. Epub 2012 May 2.
Ferrari L, Claps M, Grisanti S, Berruti A. Systemic therapy in locally advanced or metastatic adrenal cancers: A critical appraisal and clinical trial update. Eur Urol Focus. 2016 Feb;1(3):298-300.
Lalli E, Sasano H. 5th International ACC Symposium: An outlook to current and future research on the biology of adrenocortical carcinoma: Diagnostic and therapeutic applications. Horm Can. 2016;7:44-48.
Mercado-Asis LB, Wolf KI, Jochmanova I, Taieb D. Pheochromocytoma: A genetic and diagnostic update. Endocrine Practice. 2017;EP-2017-0057.
Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826-830. Epub 2013 Feb 14.
National Cancer Institute. Physician Data Query (PDQ). Adrenocortical Carcinoma Treatment. 06/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq on December 13, 2017.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. v.3.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
on December 13, 2017.
Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 07/26/16. Available at www.ncbi.nlm.nih.gov/omim/.
Przytulska J, Rogala N, Bednarek-Tupikowska G. Current and emerging therapies for adrenocortical carcinoma: Review. Adv Clin Exp Med. 2015;24(2):185-193.
Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a Lynch syndrome-associated cancer. J Clin Oncol. 2013;31(24):3012-3018. Epub 2013 Jul 22.
Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017 Jun;24(3):208-214.
Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619-4629.
Last Revised: January 2, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.